DDInter364 DDInter215
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth subsalicylate has been around for over 100 years: it was originally developed in 1901 for hygienic use and sanitation for cholera infection.[A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort. It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract. Bismuth subsalicylate is a component of HELIDAC Therapy (bismuth subsalicylate, [metronidazole], and [tetracycline]), which is a treatment regimen indicated for the eradication of _H. pylori_ for treatment of patients with _H. pylori_ infection and duodenal ulcer disease.
Chlorpropamide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Bismuth subsalicylate
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) causes {v} (Side Effect) Hyponatraemia
Hyponatraemia {u} (Side Effect) is caused by {v} (Compound) Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) causes {v} (Side Effect) Confusional state
Confusional state {u} (Side Effect) is caused by {v} (Compound) Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bismuth subsalicylate
Chlorpropamide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Bismuth subsalicylate (Compound)
Chlorpropamide (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Bismuth subsalicylate (Compound)
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Chlorpropamide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Chlorpropamide (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Bismuth subsalicylate (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Bismuth subsalicylate (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Chlorpropamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate